問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Neurology

更新時間：2023-09-19

王署君Wang, Shuu-Jiun
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王署君

List

31Cases

2006-07-01 - 2007-12-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-09-28 - 2025-10-30

Phase III

Completed
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZAVEGEPANT INTRANASAL (IN) FOR THE ACUTE TREATMENT OF MIGRAINE IN ASIAN ADULTS

  • Condition/Disease

    Migraine

  • Test Drug

    Zavegepant

Participate Sites
4Sites

Not yet recruiting3Sites

Study ended1Sites

2021-05-20 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2024-12-01 - 2028-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

  • Condition/Disease

    Menstrual Migraine (MM)

  • Test Drug

    NA

Participate Sites
5Sites

Recruiting5Sites

2024-03-01 - 2026-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2004-04-01 - 2005-04-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-01-01 - 2024-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-08-01 - 2021-07-30

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-12-01 - 2014-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-08-19 - 2024-04-30

Phase III

Completed
A 12-week phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients

  • Condition/Disease

    Chronic Migraine

  • Test Drug

    AMG334 (erenumab)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

林剛旭
China Medical University Hospital

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB